After weeks of anticipation US Treasury officials last night   to thwart US companies from moving their legal headquarters to lowertax countries The move came amid growing concern over socalled tax inversions that effectively reduce federal revenue and have been increasingly popular in the pharmaceutical industry The changes will make it harder for companies that invert to use cash that has accumulated abroad As a result AbbVies  billion deal to buy Shire may not look so attractive now Medtronic may try to renegotiate its  billion deal for Covidien and Mylan Laboratories plan to buy European assets from Abbott Laboratories may be at risk analysts say